Biomarker expression in normal fimbriae: Comparison of high- and low-grade serous ovarian carcinoma

Xuyin,Zhang; Jingxin,Ding; Xiang,Tao; Luoqi,Jia; Keqin,Hua

doi:10.3892/ol.2012.877

November 2012 Volume 4 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November 2012 Volume 4 Issue 5

Full Size Image

Article

Biomarker expression in normal fimbriae: Comparison of high- and low-grade serous ovarian carcinoma

Authors:
- Zhang Xuyin
- Ding Jingxin
- Tao Xiang
- Jia Luoqi
- Hua Keqin
View Affiliations / Copyright

Affiliations: Department of Obstetrics and Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200090, P.R. China
Pages: 1008-1012
|
Published online on: August 23, 2012

https://doi.org/10.3892/ol.2012.877
Expand metrics +

Abstract

The objective of this study was to assess the difference in fimbriae of high- and low-grade ovarian serous carcinoma (OSC). The fimbriae of normal appearance [without serous tubal intraepithelial carcinoma (STIC)] from 28 patients with high-grade OSCs and 24 patients with low-grade OSCs were assessed for the expression of 6 markers [E-cadherin, matrix metalloproteinase-2 (MMP-2), phospho‑AKT (pAKT), cyclooxygenase-2 (COX-2), vascular endothelial growth factor (VEGF) and p53] using immunohistochemistry. Sectioning and extensively examining the fimbria (SEE-FIM) was performed to exclude fimbrial involvement for all the cases. The immunostaining levels of pAKT and COX-2 were significantly higher in the fimbriae of normal appearance from high-grade OSCs compared with low-grade OSCs (61 vs. 8% and 71 vs. 21%; P=0.005 and 0.007, respectively). The immunostaining of E-cadherin was significantly higher in the fimbriae of low‑grade OSCs compared with high-grade OSCs (83 vs. 21%; P=0.003). The remaining 3 markers (MMP-2, VEGF and p53) had similar expression in low- and high-grade OSCs (21 vs. 13%; 25 vs. 21%; and 14 vs. 8%; P=0.78, 0.86 and 0.82, respectively). Our results suggest marked biological differences in the behavior of the fimbriae in high- and low-grade OSCs and indicate that proliferation, cell adhesion and the inflammatory microenvironment of fimbriae in high-grade OSCs without STIC had changed prior to p53 mutation.

View Figures

View References

1.	A MalpicaMT DeaversK LuGrading ovarian serous carcinoma using a two-tier systemAm J Surg Pathol28496504200410.1097/00000478-200404000-0000915087669
2.	RT BurksME ShermanRJ KurmanMicropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumorsAm J Surg Pathol2013191330199610.1097/00000478-199611000-000038898836
3.	RJ KurmanJD SeidmanIM ShihSerous borderline tumours of the ovaryHistopathology47310315200510.1111/j.1365-2559.2005.02186.x16115232
4.	DD BowtellThe genesis and evolution of high-grade serous ovarian cancerNat Rev Cancer10803808201010.1038/nrc294620944665
5.	Y LeeA MironR DrapkinA candidate precursor to serous carcinoma that originates in the distal fallopian tubeJ Pathol2112635200710.1002/path.209117117391
6.	DW KindelbergerY LeeA MironIntraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationshipAm J Surg Pathol31161169200710.1097/01.pas.0000213335.40358.4717255760
7.	S VaughanJI CowardRC Bast JrRethinking ovarian cancer: recommendations for improving outcomesNat Rev Cancer10719725201110.1038/nrc314421941283
8.	RJ KurmanIe-M ShihMolecular pathogenesis and extraovarian origin of epithelial ovarian cancer - shifting the paradigmHum Pathol42918931201110.1016/j.humpath.2011.03.00321683865
9.	V ShtilbansM WuDE BursteinCurrent overview of the role of Akt in cancer studies via applied immunohistochemistryAnn Diagn Pathol12153160200810.1016/j.anndiagpath.2007.12.00118325479
10.	T FujiokaY TakebayashiT KihanaExpression of E-cadherin and beta-catenin in primary and peritoneal metastatic ovarian carcinomaOncol Rep8249255200111182035
11.	K VleminckxL Vakaet JrM MareelGenetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor roleCell66107119199110.1016/0092-8674(91)90143-M2070412
12.	A MunkarahR Ali-FehmiCOX-2: a protein with an active role in gynecological cancersCurr Opin Obstet Gynecol174953200510.1097/00001703-200502000-0000915711411
13.	J KaernM AghmeshehJM NeslandPrognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?Int J Gynecol Cancer1510141022200510.1111/j.1525-1438.2005.00185.x16343177
14.	HA KennyE LengyelMMP-2 functions as an early response protein in ovarian cancer metastasisCell Cycle8683688200910.4161/cc.8.5.770319221481
15.	B SchmalfeldtD PrechtelK HärtkingIncreased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancerClin Cancer Res723962404200111489818
16.	P PaleyK StaskusK GebhardVascular endothelial growth factor expression in early stage ovarian carcinomaCancer8098106199710.1002/(SICI)1097-0142(19970701)80:1%3C98::AID-CNCR13%3E3.0.CO;2-A9210714
17.	BC CooperJM RitchieCL BroghammerPreoperative serum vascular endothelial growth factor levels: significance in ovarian cancerClin Cancer Res831933197200212374688
18.	L HeflerR ZeillingerC GrimmPreoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancerGynecol Oncol103512517200610.1016/j.ygyno.2006.03.05816750560
19.	IeM ShihRJ KurmanOvarian tumorigenesis: a proposed model based on morphological and molecular genetic analysisAm J Pathol16415111518200410.1016/S0002-9440(10)63708-X15111296

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Biomarker expression in normal fimbriae: Comparison of high- and low-grade serous ovarian carcinoma

This article is mentioned in:

Abstract

Figure 1

Related Articles